Lineage Cell Therapeutics

LCTXNYSE United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$274.228 M

$1.10 -2.65%

Close of 7 Aug 2026

Revenue

$14.6M

#3094 by revenue

Earnings

-$63.5M

Loss-making

Shares outstanding

252,907,464

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#89SAB BiotherapeuticsSABS$298.2M
#90SurrozenSRZN$297.5M
#91Lineage Cell TherapeuticsLCTX$274.2M
#92Protara TherapeuticsTARA$231.6M
#93CompugenCGEN$227.9M

Where these numbers come from

Share counts and financials for Lineage Cell Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.